Project factsheets

Learn more about the projects supported by IHI as well as the Innovative Medicines Initiative (IMI).

IHI/IMI2/IMI1

Status

Call

Programmes

Disease areas

Products

Tools and resources to improve drug development

ALL # A B C D E F G H I K L M N O P Q R S T U V W Z

Clear all filters

Displaying 23 projects and 2 programmes

INTERCEPT

Verification and validation of a biomarker panel that identifies individuals at high risk to develop Crohn’s disease allowing interception of full-blown disease development

READI

Research in Europe and diversity inclusion

Ongoing IHI Clinical trial design Conducting clinical trials Patient involvement in R&D

AB-Direct

Antibiotic distribution and recovery in tissue

Closed IMI2 Antimicrobial resistance Infectious diseases AMR Accelerator Conducting clinical trials

AMR Accelerator

Antimicrobial Resistance Accelerator

Ongoing IMI2 Antimicrobial resistance Infectious diseases AMR Accelerator Clinical trial design Conducting clinical trials

CARE

Corona accelerated R&D in Europe

Ongoing IMI2 Respiratory diseases Infectious diseases Coronaviruses Conducting clinical trials Target identification Drug discovery

EBOVAC1

Development of a prophylactic Ebola vaccine using an heterologous prime-boost regimen

Closed IMI2 Infectious diseases Ebola and related diseases Vaccines Ebola+ Clinical trial design Conducting clinical trials

EBOVAC2

Development of a prophylactic Ebola vaccine using an heterologous prime-boost regimen: phase II

Closed IMI2 Infectious diseases Ebola and related diseases Vaccines Ebola+ Conducting clinical trials

EBOVAC3

Bringing a prophylactic Ebola vaccine to licensure

Ongoing IMI2 Infectious diseases Ebola and related diseases Vaccines Ebola+ Conducting clinical trials

GNA NOW

Novel Gram-negative antibiotic now

Ongoing IMI2 Antimicrobial resistance Infectious diseases AMR Accelerator Conducting clinical trials

Impentri

Development of Impentri, an intravenous imatinib formulation for COVID-19 acute respiratory distress syndrome (ARDS)

Closed IMI2 Respiratory diseases Infectious diseases Coronaviruses Conducting clinical trials

INNODIA HARVEST

Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA

Closed IMI2 Diabetes & metabolic disorders Clinical trial design Conducting clinical trials Disease taxonomy

PD-MIND

Parkinson disease with mild cognition impairment treated with nicotinic agonist drug

Closed IMI2 Neurodegenerative diseases Conducting clinical trials

PERISCOPE

PERtussIS COrrelates of Protection Europe

Closed IMI2 Infectious diseases Vaccines Conducting clinical trials

PROTECT-trial

Proton versus photon therapy for esophageal cancer - a trimodality strategy

Ongoing IMI2 Cancer Conducting clinical trials

RespiriNTM

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Ongoing IMI2 Antimicrobial resistance Infectious diseases AMR Accelerator Conducting clinical trials Target identification

RespiriTB

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Ongoing IMI2 Antimicrobial resistance Infectious diseases AMR Accelerator Conducting clinical trials

STOPFOP

Saracatinib trial to prevent FOP

Ongoing IMI2 Rare/orphan diseases Conducting clinical trials

TRIC-TB

Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments

Closed IMI2 Antimicrobial resistance Infectious diseases AMR Accelerator Conducting clinical trials

UNITE4TB

Academia and industry united innovation and treatment for tuberculosis

Ongoing IMI2 Antimicrobial resistance Infectious diseases AMR Accelerator Clinical trial design Conducting clinical trials

COMBACTE-CARE

Combatting Bacterial Resistance in Europe - Carbapenem Resistance

Closed IMI1 Antimicrobial resistance Infectious diseases ND4BB Clinical trial design Conducting clinical trials

COMBACTE-MAGNET

Combatting bacterial resistance in Europe - molecules against Gram negative infections

Ongoing IMI1 Antimicrobial resistance Infectious diseases ND4BB Clinical trial design Conducting clinical trials Clinical networks

EPAD

European prevention of Alzheimer’s dementia consortium

Closed IMI1 Neurodegenerative diseases Alzheimer's disease Clinical trial design Conducting clinical trials

iABC

Inhaled antibiotics in bronchiectasis and cystic fibrosis

Ongoing IMI1 Antimicrobial resistance Infectious diseases ND4BB Clinical trial design Conducting clinical trials Biobanks Clinical networks Drug delivery

ND4BB

New Drugs for Bad Bugs

Ongoing IMI1 Antimicrobial resistance Infectious diseases ND4BB Clinical trial design Conducting clinical trials Clinical networks Real-world data, evidence Drug discovery Economic model

PRECISESADS

Molecular reclassification to find clinically useful biomarkers for systemic autoimmune diseases

Closed IMI1 Autoimmune diseases Diagnostics Conducting clinical trials